Skip to main content

New Clinical Trial Endpoints announced by Kidney Health Initative (KHI) and the Oxalosis and Hyperoxaluria Foundation (OHF)

New clinical trial end points identified by a Kidney Health Initiative (KHI) workgroup, in partnership with the Oxalosis and Hyperoxaluria Foundation (OHF), offer hope for people with primary hyperoxaluria. Today, the US Food and Drug Administration (FDA) has no approved therapies for primary hyperoxaluria. Several pharmaceutical companies are conducting clinical trials for new drug targets in this rare disease and the end points identified in the recent publication in the Clinical Journal of the American Society of Nephrology (CJASN) will catalyze the approval of these new therapies.

Outside Link

Add new comment

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.